Clinical Trials

Find a Trial

Trial Summary

Protocol No.MK-3475-629
Principal InvestigatorGrethlein, Sara
PhasePhase II
Age GroupAdult
TitleA Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
DescriptionThe purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic cutaneous Squamous Cell Carcinoma (R/M cSCC) that is not amenable to surgery and/or radiation and/or systemic therapies.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Diagnosis of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
For a full list of participation criteria, please visit
Applicable Disease SitesOther Skin
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment
ContactAnya Kjeldsen, Phone:
Pager: 317-312-3214